Latest News and Press Releases
Want to stay updated on the latest news?
-
Mynzepli® (aflibercept) is approved in all European Economic Area member countries for the treatment of various retinal diseases including neovascular (wet) age-related macular degeneration...
-
Lyfið verður markaðssett í Evrópu undir heitinu Mynzepli og verður notað til meðferðar við augnbotnahrörnun og fleiri augnsjúkdómumMilljónir Evrópubúa þurfa að takast á við áhrif...
-
Mynzepli® (aflibercept) is approved in all European Economic Area member countries for the treatment of various retinal diseases including neovascular (wet) age-related macular degeneration...
-
REYKJAVIK, ISLAND (20 augusti 2025) — Alvotech (NASDAQ: ALVO), ett globalt bioteknikföretag som specialiserat sig på utveckling och tillverkning av biosimilarer för patienter över hela världen,...
-
REYKJAVIK, ICELAND (August 20, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced...
-
Strong performance driven by over 200% growth in product revenues year-on-year Best quarter in Alvotech’s history in terms of operating cash flows Continued expansion of...
-
Yfir 200% aukning á tekjum af sölu lyfja á fyrri helmingi ársins miðað við sama tíma í fyrraAnnar ársfjórðungur sá besti í sögu félagsins hvað varðar handbært fé frá rekstri Nýir samningar um...
-
Strong performance driven by over 200% growth in product revenues year-on-year Best quarter in Alvotech’s history in terms of operating cash flowsContinued expansion of commercial partnerships for...
-
REYKJAVIK, ISLAND (6 AUGUSTI, 2025) – Alvotech (NASDAQ:ALVO SDB), ett globalt biofarmaceutiskt företag som specialiserar sig på utveckling och tillverkning av biosimilära läkemedel för patienter...
-
REYKJAVÍK (6. ágúst 2025) Alvotech (NASDAQ: ALVO) mun senda út tilkynningu með uppgjöri fyrir fyrri helming ársins 2025 eftir lokun markaða í Bandaríkjunum, miðvikudaginn 13. ágúst nk. Fundur til...